Course Learning Objectives

Upon completion of this activity, participants should be able to:

• Assess the utility of genomic tools to assess recurrence risk and predict benefit to systemic therapies
• Outline clinical guidelines for assessment, diagnosis, and ongoing management of osteoporosis as well as bone metastasis treatment and prevention  in women with breast cancer.
• Describe optimal use of current targeted agents for ER positive and HER2 overexpressing  breast cancer.
• Discuss novel targeted approaches to triple negative breast cancer (TNBC) in early and metastatic breast cancer.